Warren A. Kaplan, PhD, JD, MPH

Clinical Assistant Professor, Global Health
Warren Kaplan
(617) 414-1152wak@bu.edu
Crosstown Center
View full profile at BUMC

Biography

Warren A. Kaplan, PhD, JD, MPH is a Clinical Assistant Professor in the Department of Global Health at the Boston University School of Public Health, where he is a member of the World Health Organization Collaborating Center in Pharmaceutical Policy. His research focuses on pharmaceutical and legal policies related to health system strengthening and evaluations of medicines access and utilization. His current interests and expertise include intellectual property policy, antimicrobial resistance, medicines price analysis, generic medicines policies, quality use of medicines, access to medicines for non-communicable diseases and the role of the private sector to promote equitable access and efficient use of medicines in low and middle income countries. Dr. Kaplan has carried out cross-national comparison of medicines consumption and trade using sales and customs data bases to inform policy making about adequate use of insulin and other essential medicines. Between 1995 and 2001 he was Assistant General Counsel at Biogen, the pharmaceutical company in Cambridge Massachusetts and coordinated and established Biogen's worldwide patent filings and all intellectual property related activities for: Biogen's FDA approved psoriasis drug, including negotiating settlement of trademark disputes and collaborative R&D agreements between Biogen and third parties totaling about $100 M . He initiated and prepared due diligence reviews for 30 business opportunities and was responsible for $50-60M per year of Biogen's R&D budget and advised Biogen on global intellectual property strategies. Between 2003-2004 Dr. Kaplan was Technical Officer at the World Health Organization Geneva, Switzerland in the Essential Drugs & Medicine/Policy, Access, Rational Use Priority Medicines Project. This was a $500,000 Dutch funded project given to the WHO which was designed to advise the European Union on best priorities for pharmaceutical R&D for the 7th EU Framework Program. Dr. Kaplan developed the methodology for uncovering research and market "gaps" in treatment for high and medium burden diseases and prepared several “state of the art" reviews of pharmaceutical "gaps" for cancer, HIV/AIDS, alcoholic liver disease, chronic obstructive pulmonary disease. Between 2007-2009, he also served as a WHO Technical Officer for the Priority Medical Devices Project- a $1,000,000 Dutch funded project given to the WHO- designed to advise the European Union on best priorities for R&D and access to medical devices in developing countries. Dr. Kaplan also helped to developed survey methodologies for uncovering research and market "gaps" in development and use of medical devices for high and medium burden diseases. He has worked as a technical adviser for various international organizations, among them the Doctors Without Borders, the Clinton Foundation, the Alliance for Health Systems and Policy Research, Health Action International. He has published widely in international peer review journals in science, law and public health such as Nature, The Lancet, World Health Organization Bulletin, Health Policy and Planning, Health Policy, PloS One, Tropical Medicine and International Health. He received his training as an ecologist and microbiologist from Boston University, his post-doctoral training in biogeochemistry from Harvard University, his law degree from Suffolk University and his MPH from Boston University.

Education

  • Boston University, PhD
  • Boston University School of Public Health, MPH
  • Texas A&M University, MS
  • Queens College, City University of New York, BA
  • Suffolk University, JD

Classes Taught

  • SPHGH891
  • SPHPH740

Publications

  • Published on 9/13/2018

    Lee YT, Lee YH, Kaplan WA. Is Taiwan's National Health Insurance a perfect system? Problems related to health care utilization of the aboriginal population in rural townships. Int J Health Plann Manage. 2018 Sep 13. PMID: 30211960.

    Read at: PubMed
  • Published on 9/13/2018

    Gallegos JE, Boyer C, Pauwels E, Kaplan WA, Peccoud J. The Open Insulin Project: A Case Study for 'Biohacked' Medicines. Trends Biotechnol. 2018 Dec; 36(12):1211-1218. PMID: 30220578.

    Read at: PubMed
  • Published on 5/1/2018

    Sharma A, Bhandari PM, Neupane D, Kaplan WA, Mishra SR. Challenges constraining insulin access in Nepal-a country with no local insulin production. Int Health. 2018 05 01; 10(3):182-190. PMID: 29617832.

    Read at: PubMed
  • Published on 9/7/2017

    Barlam TF, Morgan JR, Kaplan WA, Outterson K, Pelton SI. Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. J Pediatric Infect Dis Soc. 2017 Sep 07. PMID: 28992176.

    Read at: PubMed
  • Published on 8/22/2017

    Sharma A, Mishra SR, Kaplan WA. Trade in medicines and the public's health: a time series analysis of import disruptions during the 2015 India-Nepal border blockade. Global Health. 2017 Aug 22; 13(1):61. PMID: 28830500.

    Read at: PubMed
  • Published on 5/16/2017

    Kaplan WA, Ashigbie PG, Brooks MI, Wirtz VJ. Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies. J Pharm Policy Pract. 2017; 10:17. PMID: 28523128.

    Read at: PubMed
  • Published on 1/16/2017

    Ewen M, Kaplan W, Gedif T, Justin-Temu M, Vialle-Valentin C, Mirza Z, Regeer B, Zweekhorst M, Laing R. Prices and availability of locally produced and imported medicines in Ethiopia and Tanzania. J Pharm Policy Pract. 2017; 10:7. PMID: 28116107.

    Read at: PubMed
  • Published on 10/12/2016

    Sharma A, Kaplan WA. Challenges constraining access to insulin in the private-sector market of Delhi, India. BMJ Glob Health. 2016 Nov; 1(3):e000112. PMID: 28588966.

    Read at: PubMed
  • Published on 10/10/2016

    Lee YH, Ang TFA, Chiang TC, Kaplan WA. Growing concerns and controversies to Taiwan's National Health Insurance-what are the lessons from mainland China, South Korea and Singapore? Int J Health Plann Manage. 2018 Jan; 33(1):e357-e366. PMID: 27723118.

    Read at: PubMed
  • Published on 10/4/2016

    Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries". Circulation. 2016 10 04; 134(14):e305-e306. PMID: 27698055.

    Read at: PubMed

View 48 more publications:View full profile at BUMC

News & In the Media